A medical center recently announced the completion of the world's first 3D bioprinted corneal transplant surgery. This groundbreaking procedure was performed on October 29, 2025. The patient, who received a PB-001 corneal implant developed by Precise Bio, is recovering well, marking the successful application of the world's first functional cornea manufactured using 3D bioprinting technology based on living human cells.

The technical team utilized a proprietary robotic 3D biomanufacturing system, achieving the breakthrough capability of expanding production from a single donor cornea to hundreds of lab-grown implants. Compared to traditional corneal transplantation, this technology not only perfectly replicates the optical transparency and biomechanical properties of natural corneas but also overcomes the bottleneck of donor shortage through long-term cryopreservation technology – potentially benefiting 13 million patients worldwide awaiting corneal transplants.

This technological breakthrough stems from interdisciplinary innovation in cell biology, biomaterials, and 3D bioprinting technology. The Phase 1 clinical trial is currently progressing steadily, with top-line results expected in the second half of 2026. The research team stated that if subsequent phases are successful, the technology is expected to achieve large-scale clinical application within 3-5 years, fundamentally changing the supply landscape of corneal transplantation worldwide.

The success of this surgery not only validates the feasibility of 3D bioprinting technology in manufacturing complex human tissues but also demonstrates the immense potential of biomanufacturing technology in addressing global medical resource shortages. With technological advancements and further clinical trials, this innovative therapy may become a landmark breakthrough in the field of regenerative medicine.